Biophytis announces the deployment of its partnership strategy in the obesity sector

Biophytis SA, a biotechnology company focused on developing therapies for age-related diseases, today revealed the expansion of its partnership strategy specifically for the area of obesity.

Headquartered in Paris and Cambridge, MA, the company aims to integrate strategic partnerships by licensing its lead product, BIO101, to pharmaceutical companies capable of co-developing and commercializing this potential obesity drug. BIO101 is currently in phase 2 of clinical development. The company highlights the importance of this market, particularly in the United States, China and Brazil, where obesity has high prevalence rates.

The next major step for Biophytis will be its participation in the BIO US conference in San Diego, aimed at attracting possible partners and strengthening its presence on the international pharmaceutical scene.